Quick Answer
IMMUCELL CORP /DE/ reported Operating Income Loss of $1.65 million for the year ending 2025.
- IMMUCELL CORP /DE/ showed an increase of +200.6% in Operating Income Loss from 2024 to 2025.
- This data is from IMMUCELL CORP /DE/'s annual report (Form 10-K), filed with the SEC on March 30, 2026.
- XBRL data for this metric is available from 2009 to 2025 (17 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 17 years of available data (2009 to 2025), IMMUCELL CORP /DE/'s Operating Income Loss has grown by 411.2%.
- Historical annual values: Fiscal year 2025: $1.65 million | Fiscal year 2024: -$1.64 million | Fiscal year 2023: -$5.75 million | Fiscal year 2022: -$2.30 million | Fiscal year 2021: $257.4 thousand | Fiscal year 2020: -$1.38 million | Fiscal year 2019: -$953.9 thousand | Fiscal year 2018: -$1.45 million | Fiscal year 2017: -$242.8 thousand | Fiscal year 2016: $890.2 thousand | Fiscal year 2015: $2.12 million | Fiscal year 2014: -$206.4 thousand | Fiscal year 2013: -$19.6 thousand | Fiscal year 2012: $245.0 thousand | Fiscal year 2011: -$632.7 thousand | Fiscal year 2010: -$690.3 thousand | Fiscal year 2009: -$529.9 thousand.
- Data sourced from SEC EDGAR public filings as of June 23, 2026.
Last verified: